{"id":"4dfd0d97df2e","type":"article","url":"https://hartvaat.nl/2026/03/07/lancet-seminar-atriumfibrilleren-in-2026/","title":"Lancet-seminar: atriumfibrilleren in 2026","title_en":"Atrial fibrillation","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts","internist"],"tags":["anticoagulatie-kwetsbare-ouderen","pulsed-field-ablatie-atriumfibrilleren"],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02166-X/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02166-X/fulltext","authors":["Deirdre A Lane","Jason G Andrade","Elena Arbelo","Giuseppe Boriani","Jeroen M Hendriks","So-Ryoung Lee","Gregory Y H Lip","Jonathan Mant","Melissa E Middeldorp"],"significance":9,"published":"2026-03-12","source_date":"2026-03-07","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/"],"congress":"","summary_en":"This comprehensive Lancet Seminar provides a state-of-the-art overview of atrial fibrillation, covering its rising global prevalence of 37.6 million affected individuals, the impact of wearable device-based detection, contemporary management strategies including early rhythm control and pulsed field ablation, and integrated AF care pathways.","created":"2026-07-03T10:32:33Z","updated":"2026-07-03T18:39:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Dit uitgebreide Lancet-seminar biedt een actueel overzicht van atriumfibrilleren, dat wereldwijd 37,6 miljoen mensen treft. Besproken worden de toegenomen detectie door draagbare technologie, het risico op beroerte, hartfalen en overlijden, en de huidige behandelstrategieën. De prevalentie zal naar verwachting verdubbelen in de komende 35 jaar.","abstract_original":"Atrial fibrillation affects approximately 37·6 million people worldwide, with the prevalence predicted to double over the next 35 years. The ubiquitous use of wearable devices and other technologies with inbuilt diagnostic algorithms allows greater detection of atrial fibrillation among the general public than previously. Atrial fibrillation increases the risk of stroke and thromboembolism, heart failure, and death, and is associated with reductions in quality of life. Patients with atrial fibrillation frequently have comorbidities, and the accumulation of risk factors, including lifestyle factors associated with poorer health outcomes, and increasing age, often adds to the complexity of managing such patients."}